Understanding how PD-L1 signaling affects liver health and disease
Official title: PD-L1 reverse signaling in liver homeostasis and disease
Funded at University of Colorado Denver · NIH-11145555 · Data updated 2026-11-12
This study is looking at how a specific signaling process in the liver affects the immune system during infections and diseases, which could help us understand liver problems better and find new ways to improve liver health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | January 1, 2025 |
| Project end | April 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $28,803 |
| NIH project number | 3R01AI186275-01S1 |
| Project ID | NIH-11145555 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from acute or chronic liver diseases, particularly those with metabolic dysfunction or infections.
✕Less likely to help
Patients with liver conditions unrelated to immune regulation or those not experiencing acute or chronic liver diseases may not benefit from this research.
What this research studies
This research investigates the role of PD-L1 reverse signaling in the liver, focusing on its impact during acute and chronic infections and diseases. By using a mouse model with specific mutations in PD-L1, the study aims to uncover how this signaling pathway influences immune responses, particularly in the migration and activation of immune cells. The findings could provide insights into liver conditions like metabolic dysfunction-associated steatohepatitis (MASH) and help identify potential therapeutic targets for improving liver health.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance liver function and immune response in patients with liver diseases.
How similar studies have gone: Previous research has shown promising results in understanding immune regulation in liver diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Tamburini, Beth Ann — University of Colorado Denver
- Study coordinator: Tamburini, Beth Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.